Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. - Wikidata - awgldk - TriplyDB

Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.

Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.

http://www.wikidata.org/entity/Q53305562

about

Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data.Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis.Multicenter validation of the value of BASFI and BASDAI in Chinese ankylosing spondylitis and undifferentiated spondyloarthropathy patients.Sclerosing mesenteritis successfully treated with a TNF antagonist Update on the treatment of ankylosing spondylitis.Spondyloarthritides: evolving therapies Infliximab: 12 years of experience Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis.Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab.Detection of Active Sacroiliitis with Ankylosing Spondylitis through Intravoxel Incoherent Motion Diffusion-Weighted MR Imaging.First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.ASAS/EULAR recommendations for the management of ankylosing spondylitis.Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: a dynamic population modelling study.Infliximab for the treatment of ankylosing spondylitis.Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides.Vertebral body corner oedema vs gadolinium enhancement as biomarkers of active spinal inflammation in ankylosing spondylitis.Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis.TNFalpha blockade in human diseases: an overview of efficacy and safety.Cytokine levels in the serum of healthy subjects Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease.Tumor necrosis factor as a therapeutic target of rheumatologic disease.Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.Infliximab in the treatment of ankylosing spondylitis.Long-term use of adalimumab in the treatment of rheumatic diseases.Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients.Anti-TNF-alpha therapy with infliximab in spondyloarthritides.Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future.Etanercept: efficacy and safety for approved indications.Biologic agents in inflammatory eye disease.Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review.The SAPHO syndrome revisited with an emphasis on spinal manifestations.Valuing treatment with infliximab for ankylosing spondylitis using a willingness-to-pay approach.Management of ankylosing spondylitis with infliximab.Identification of small molecule inhibitors of RANKL and TNF signalling as anti-inflammatory and antiresorptive agents in mice.

P2860

Q21195369-921C0B1F-109F-471E-AD04-C8FFB9DC2314 Q24816557-A55041C9-D967-4A7D-9B5B-EC8129A772E5 Q31142567-F363F1C7-0FDF-4883-B82F-41C4267D9145 Q33923298-928317E1-BF60-4198-8117-DC0D03E66C28 Q34511356-25214F3D-7354-47D9-83F8-0C653AE0EC00 Q34532478-8F2F53BA-832F-4A86-BDD8-BFCA0D4D2345 Q34592673-BB86741D-ABBC-4768-B414-00B0A484F2C1 Q34613907-BE8A1FEF-861C-4D44-B9FA-3BD7F31CB912 Q35070446-838B801D-C79F-419C-87A8-A37AF55FB215 Q35535807-F014B767-7621-4386-A677-8AB04EA48CF6 Q35554794-5290C193-F9F4-4700-8426-6AA404584C00 Q35560343-F189B608-3E11-4ACF-9124-78DD4145EF4B Q35636900-8E49C1A6-E36C-4145-9711-810EDFEB03D9 Q35637012-BB2A49CF-3B67-4B21-8930-F59B33731EBC Q35759171-E9796C8C-86D7-4CC5-B4A0-662E1D6DA295 Q35896670-C3682E28-9FB4-47A3-9CD2-C23CCE48E52D Q36135031-2FAF903B-F5F0-4E20-BB8A-CFEBB8D29411 Q36210882-3551403F-F1B1-48FC-AF52-2269FE7F209F Q36245711-99078FC0-8D65-4980-AFC1-613807E63134 Q36365524-694C0652-C8EF-4659-8AAF-A0006CE1D76A Q36458447-2FCF7379-9968-4712-B2D6-ED33ED8E3915 Q36536861-54F1B59F-8E2B-4A0A-9649-479A5B1A5906 Q36711758-3D2D2426-9BEA-4C56-A911-9F0FC8386429 Q36724093-483BC956-C116-4883-A390-7EB2F337BB0C Q36849136-2E8D62EC-0AA1-4956-BCDF-800F29B8BCEB Q37008829-9D645D90-C03A-43E4-AB75-9D1F832765E9 Q37172795-7E588304-F334-4C01-BA51-668288EC21B4 Q37290474-0625F051-844C-4FDB-8C28-2604571A2F95 Q37358124-35E44AC6-42F4-482E-97C3-5B844BAB5D99 Q37465416-4FA59220-FA10-4225-9ED4-479864014643 Q37690355-2EB5BABF-8845-441B-BEDC-BB8573328BF9 Q37729028-F20A96FF-570A-41EF-A72B-BEA1483FC477 Q37882064-7DF7B2A4-DB43-447C-BE98-C31416917017 Q37954714-32CC14AC-DB94-4415-A060-80C2BFE312B6 Q37997772-9472B34E-65FB-4643-9B02-25D380B05CE5 Q38246381-1D344AA0-631C-46CA-B980-9BC7852B4ED2 Q38261538-EC567D4D-5D3C-4C4A-B91D-519759FD1A05 Q38748204-057BCDCA-0416-4EAD-B843-9066043B3667 Q38993236-1CC0DBAF-E037-46E9-9602-E70829B00C83 Q39085876-B470B7B7-E055-4ADA-A5B4-7AB0583AF3C5

P2860

Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.

http://www.wikidata.org/entity/Q53305562

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Persistent clinical response t ...... sing spondylitis over 3 years.

@en

Persistent clinical response t ...... sing spondylitis over 3 years.

@nl

type

label

Persistent clinical response t ...... sing spondylitis over 3 years.

@en

Persistent clinical response t ...... sing spondylitis over 3 years.

@nl

prefLabel

Persistent clinical response t ...... sing spondylitis over 3 years.

@en

Persistent clinical response t ...... sing spondylitis over 3 years.

@nl

P1433

Q53305562-CE54FA1D-5173-486A-9C3A-041AE7F8EA84

P1476

Q53305562-F25AEFC1-8651-4822-8401-C6E0656D7930

P2093

Q53305562-0395319F-A339-469D-B271-B5C3A81EEBF2

Q53305562-1806E011-1FD4-4BDC-9467-0FF68169DBB9

Q53305562-1C84D0EB-1D30-4C5E-B83D-A8CEB5D7453C

Q53305562-2D5030F5-548C-41D0-9D33-4E7AB19CE6CF

Q53305562-3EA53151-F944-453C-B9E7-AC7827B5C297

Q53305562-42B2FC4D-AD63-4E7B-88A7-8BD418150AA0

Q53305562-54B23082-60D2-411A-87B8-F77EDE150943

Q53305562-67CB7A10-047C-47B0-A88A-577C3FF87AF2

Q53305562-79174D5C-CB67-4C4B-B781-9B0FEA154C88

Q53305562-8D88C940-428E-49A1-BA06-3563424C9C6E

P2860

Q53305562-160BFAB4-44FA-47E0-9261-386B4906F316

Q53305562-1915D074-BE78-4D12-9488-BABBBAB1A27F

Q53305562-3D8B86DE-0BD2-41F4-91D5-14479EEE757C

Q53305562-3D8EE809-E497-4F8B-8A19-C47A30CE936E

Q53305562-436F0A13-12C8-45C7-A851-25348F0CD2BC

Q53305562-45AD1FAF-613F-4CDE-A682-A774445CFB88

Q53305562-4FAB91B3-35B9-49D5-ABC1-109488E5123B

Q53305562-651BE429-0F44-4956-915D-36F34B19563B

Q53305562-7C84A646-08F1-4EC7-8509-B0F896B64D93

Q53305562-9ACC1E4B-7B83-45F5-B707-28B5EB40517B

P304

Q53305562-7629E0F9-EB6E-4879-91A3-2EEDC8830905

P31

Q53305562-15EAF18C-AB35-499B-97B1-C424063F9646

P356

Q53305562-089D4C27-8372-42DC-A688-A7E183B64EF3

P433

Q53305562-77FD9CD4-5F9F-42E9-B27A-BAE054D9B135

P478

Q53305562-7B21C86E-D106-4FD7-9B24-D2DD19920AD8

P577

Q53305562-1446F8C7-28D0-497B-8619-D10ACA8CB6DC

P5875

Q53305562-0E48860A-FBF5-499D-9ECB-048729C77D5D

P698

Q53305562-028F9365-FAF4-4405-93AA-AF09CFB64521

P921

Q53305562-56B7F4A0-2974-431B-89F4-DBF90860D854

Q53305562-7E746847-2538-46BB-ACAB-813CFD90D26B

Q53305562-832FA302-0545-4A8B-A346-2B86B2D70854

Q53305562-AD7A068C-111A-42DE-872C-743A66740CF5

P356

P1433

P1476

Persistent clinical response t ...... sing spondylitis over 3 years.

@en

P2093

Alten R

http://www.w3.org/2001/XMLSchema#string

Baraliakos X

http://www.w3.org/2001/XMLSchema#string

Brandt J

http://www.w3.org/2001/XMLSchema#string

Braun J

http://www.w3.org/2001/XMLSchema#string

Burmester G

http://www.w3.org/2001/XMLSchema#string

Gromnica-Ihle E

http://www.w3.org/2001/XMLSchema#string

Kellner H

http://www.w3.org/2001/XMLSchema#string

Listing J

http://www.w3.org/2001/XMLSchema#string

Schneider M

http://www.w3.org/2001/XMLSchema#string

Sieper J

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromsø, northern Norway

The MOS 36-ltem Short-Form Health Survey (SF-36)

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy.

The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients.

Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries.

Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis.

Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis.

Biological therapies in the spondyloarthritides--the current state.

The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).

P304

670-676

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KEH584

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7976404

http://www.w3.org/2001/XMLSchema#string

P698

15757965

http://www.w3.org/2001/XMLSchema#string

P921